Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26926087 |
US |
1 | |
Malignant neoplasm progression, |
||||
SONIDEGIB, |
||||
| 102 | 26926193 |
BR |
70 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 103 | 26926359 |
JP |
7 | 2 |
Malignant neoplasm progression, Hepatic function abnormal, Malaise, Decreased appetite, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, APREPITANT, CISPLATIN, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 104 | 26926530 |
BR |
70 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 105 | 26926591 |
US |
65 | |
Malignant neoplasm progression, |
||||
LENALIDOMIDE, |
||||
| 106 | 26914685 |
BR |
66 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 107 | 26914691 |
BR |
53 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 108 | 26914700 |
BR |
74 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 109 | 26914762 |
AU |
||
Malignant neoplasm progression, Ovarian cancer, Off label use, |
||||
BEVACIZUMAB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, CARBOPLATIN, FULVESTRANT, LETROZOLE, LETROZOLE TABLETS, TAMOXIFEN CITRATE, |
||||
| 110 | 26914795 |
AU |
||
Malignant neoplasm progression, Ovarian cancer, Off label use, |
||||
BEVACIZUMAB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, CARBOPLATIN, FULVESTRANT, LETROZOLE, LETROZOLE TABLETS, TAMOXIFEN CITRATE, |
||||
| 111 | 26915578 |
UZ |
2 | |
Malignant neoplasm progression, Chronic myeloid leukaemia, |
||||
| 112 | 26915713 |
MX |
51 | 2 |
Breast cancer, Malignant neoplasm progression, Cardio-respiratory arrest, Hepatitis, Asthenia, Back pain, Pruritus, Hair growth abnormal, Weight increased, Increased appetite, Dyspepsia, Drug hypersensitivity, Pharyngeal inflammation, Dyspepsia, Pharyngeal inflammation, Dysphagia, Decreased immune responsiveness, Anaemia, Constipation, Dizziness, Influenza, Pain, Malaise, Arthralgia, Pyrexia, Eye infection, Photophobia, Dry skin, Weight decreased, Bone pain, Drug ineffective, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 113 | 26915719 |
BR |
2 | |
Vulvovaginal injury, Spinal fracture, Vein rupture, Metastases to bone, Metastases to spine, Metastases to liver, Metastasis, Haemorrhage, Hydronephrosis, Urinary retention, Seizure, Breast cancer, Malignant neoplasm progression, Nail cuticle fissure, Epistaxis, Dry skin, Dry mouth, Constipation, Vulvovaginal dryness, Drug ineffective, Petechiae, Skin tightness, Visual impairment, Skin fissures, Skin atrophy, Dry throat, Nasal mucosal disorder, Rhinalgia, Secretion discharge, Insomnia, Throat irritation, Hair texture abnormal, Skin exfoliation, Breast disorder, Tumour marker increased, Calcification metastatic, Weight increased, Flatulence, Reflux gastritis, Hiatus hernia, Gastritis, Muscle spasms, Vitamin B12 deficiency, Feeding disorder, Balance disorder, Head injury, Fall, Dermal absorption impaired, Thermal burn, Nasal congestion, Eye swelling, Phlebitis, Rhinitis allergic, Allergic sinusitis, Decreased immune responsiveness, Gastric polyps, Skeletal injury, Pelvic bone injury, Epistaxis, Oropharyngeal discomfort, Hypersensitivity, Discomfort, Quality of life decreased, Rectocele, Bone lesion, Product distribution issue, Thinking abnormal, Feeling abnormal, Carbohydrate antigen 15-3 increased, PIK3CA-activated mutation, Quality of life decreased, Feeding disorder, Sensory disturbance, Skin discolouration, COVID-19, Bone pain, Condition aggravated, Anosmia, Malaise, Gene mutation, Urinary tract infection, Oral pain, Muscle injury, Hepatic mass, Dysbiosis, Oral disorder, Speech disorder, Chills, Lip swelling, Gait disturbance, Gastrointestinal disorder, Pain, Depressed mood, Myalgia, Atrophic vulvovaginitis, Nasal disorder, Head injury, Malaise, Tumour marker abnormal, Central nervous system lesion, Hepatic lesion, Cervix disorder, Uterine leiomyoma, Bacteriuria, Swelling face, Pruritus, Erythema, White blood cell count decreased, Nausea, Peripheral swelling, Vomiting, Diarrhoea, Nasopharyngitis, Dizziness, Abdominal pain upper, Cough, Retching, Fatigue, Sinusitis, Infection, Rhinitis, Abdominal pain, Dyspnoea, Abdominal discomfort, Drug resistance, Pain, Pain in extremity, Head discomfort, Decreased appetite, Vision blurred, Illness, Weight decreased, Arthralgia, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, PANTOPRAZOLE, FULVESTRANT, FULVESTRANT, FULVESTRANT, FULVESTRANT, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ALPELISIB, LORATADINE, LORATADINE ORAL, LORATADINE, LORATADINE ORAL, LORATADINE, LORATADINE ORAL, EXEMESTANE, CLONAZEPAM, CAPECITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, ERGOCALCIFEROL, |
||||
| 114 | 26915756 |
JP |
1 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 115 | 26916632 |
JP |
7 | 1 |
Malignant ascites, Malignant neoplasm progression, |
||||
BELZUTIFAN, |
||||
| 116 | 26916907 |
KR |
1 | |
Malignant neoplasm progression, Off label use, |
||||
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, |
||||
| 117 | 26916962 |
KR |
2 | |
Pneumonia, Malignant neoplasm progression, Off label use, |
||||
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, |
||||
| 118 | 26917120 |
RU |
70 | 1 |
Malignant neoplasm progression, Gene mutation, Prostatic specific antigen increased, |
||||
TRIPTORELIN, TRIPTORELIN, TRIPTORELIN, TRIPTORELIN, DOCETAXEL, DOCETAXEL ANHYDROUS, ENZALUTAMIDE, |
||||
| 119 | 26917127 |
US |
1 | |
Malignant neoplasm progression, |
||||
ACALABRUTINIB, |
||||
| 120 | 26917205 |
BR |
72 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 121 | 26917572 |
TR |
||
Death, General physical health deterioration, Malignant neoplasm progression, |
||||
TALAZOPARIB, |
||||
| 122 | 26918174 |
CA |
59 | 2 |
Blood pressure increased, Syncope, Blood iron decreased, Cystitis, Cellulitis, Back pain, Neuralgia, Pain, Hypoaesthesia, Paraesthesia, Diabetes mellitus, Cholelithiasis, Haemorrhage, Hypothyroidism, Endometrial cancer stage I, Second primary malignancy, Nephrolithiasis, Renal impairment, Renal failure, Procedural pain, Carcinoid tumour, Metastases to ovary, Metastases to fallopian tube, Metastases to bladder, Malignant neoplasm progression, Palpitations, Arthralgia, Subcutaneous haematoma, Pain in extremity, Muscle spasms, Peripheral swelling, Serum serotonin increased, Vertigo, Urine output decreased, Myalgia, Contusion, Hepatic pain, Muscle tightness, Groin pain, Nasopharyngitis, White blood cell count increased, Haemoglobin decreased, Urinary tract infection, Acne, Liver function test increased, Hypomenorrhoea, Polyp, Blood urine present, Abdominal adhesions, Endometriosis, Endometrial hyperplasia, Poor quality sleep, Pyrexia, Chills, Cough, Migraine, Anaemia, Blood pressure systolic decreased, Blood pressure diastolic decreased, Joint swelling, Arthritis, Crystal arthropathy, Gout, Joint stiffness, Malaise, Peripheral swelling, Erythema, Joint swelling, Rash pruritic, Asthenia, Heart rate decreased, Vomiting, Dizziness, Abdominal pain, Abdominal tenderness, Rash papular, Diarrhoea, Fatigue, Nausea, Decreased appetite, Injection site mass, Injection site pain, Injection site pain, Injection site reaction, Injection site erythema, Needle issue, |
||||
AMLODIPINE, AMLODIPINE, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CLOPIDOGREL, CLOPIDOGREL BISULFATE, |
||||
| 123 | 26918366 |
IN |
62 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Adenocarcinoma, Metastasis, Metastases to lymph nodes, Metastases to lung, Metastases to pleura, Metastases to bone, Hepatotoxicity, Bone lesion, Hepatic lesion, Hepatomegaly, Back pain, Eastern Cooperative Oncology Group performance status worsened, Full blood count decreased, Tooth infection, Product availability issue, Off label use, |
||||
RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, TELMISARTAN, |
||||
| 124 | 26918541 |
EU |
2 | |
Malignant neoplasm progression, Diffuse large B-cell lymphoma refractory, Off label use, |
||||
OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, METHYLPREDNISOLONE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CISPLATIN, CISPLATIN, CISPLATIN, MEROPENEM, MEROPENEM, CYTARABINE, CYTARABINE, CYTARABINE, FILGRASTIM, FILGRASTIM, FILGRASTIM, FILGRASTIM, FILGRASTIM, VINCRISTINE SULFATE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, RITUXIMAB AND HYALURONIDASE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ERYTHROPOIETIN, ERYTHROPOIETIN, ERYTHROPOIETIN, ERYTHROPOIETIN, ERYTHROPOIETIN, ALBUMIN HUMAN, ALBUMIN HUMAN, ALBUMIN HUMAN, ALBUMIN HUMAN, ALBUMIN HUMAN, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, ERYTHROPOIETIN, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 125 | 26919434 |
BR |
48 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 126 | 26919443 |
EU |
50 | 2 |
Spinal stenosis, Malignant neoplasm progression, |
||||
ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, GOSERELIN, |
||||
| 127 | 26920957 |
EU |
42 | 2 |
Posterior reversible encephalopathy syndrome, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 128 | 26923947 |
71 | 2 | |
Renal cancer, Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 129 | 26909538 |
NZ |
||
Malignant neoplasm progression, |
||||
ATEZOLIZUMAB, |
||||
| 130 | 26909838 |
CL |
51 | 2 |
Osteonecrosis, Metastasis, Neutrophil count decreased, Breast cancer, Malignant neoplasm progression, Rectal cancer, Second primary malignancy, Metastases to bone, Bone pain, Pain, Back pain, Illness, Sinus bradycardia, Full blood count abnormal, Mean cell volume increased, Mean cell haemoglobin increased, Red cell distribution width increased, Anisocytosis, Macrocytosis, Elliptocytosis, Confusional state, Pain in extremity, Movement disorder, Polychromic red blood cells present, Neutrophil toxic granulation present, Red blood cell poikilocytes present, Lymphocyte percentage abnormal, Red blood cell count increased, Blood alkaline phosphatase decreased, Vision blurred, Red blood cell count decreased, White blood cell count decreased, Blood creatinine abnormal, Blood urea abnormal, Aspartate aminotransferase increased, Platelet count decreased, Platelet count decreased, Gait disturbance, Visual impairment, Eating disorder, Overweight, Insomnia, Anxiety, Depressed mood, Cytogenetic analysis abnormal, Platelet count increased, Inappropriate schedule of product administration, |
||||
FULVESTRANT, LETROZOLE, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, VISCUM ALBUM FRUITING TOP, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 131 | 26910127 |
AU |
2 | |
Malignant neoplasm progression, Ovarian cancer, Off label use, |
||||
BEVACIZUMAB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, CARBOPLATIN, FULVESTRANT, LETROZOLE, LETROZOLE TABLETS, TAMOXIFEN CITRATE, |
||||
| 132 | 26910130 |
CA |
2 | |
Cerebrovascular accident, Fall, Cerebrovascular accident, Pneumonia, Fall, Hypovolaemia, Peripheral swelling, Malaise, Diarrhoea, Abdominal discomfort, Fatigue, Arthropod bite, Joint swelling, Erythema, Nausea, Hypertension, Wrist fracture, Rib fracture, Head injury, Suicide attempt, Bronchitis, Productive cough, Unresponsive to stimuli, Malignant neoplasm progression, Suicidal ideation, Vasculitis, Depression, Depressed mood, Nervousness, Nervousness, Psychiatric symptom, Blood pressure increased, Depression, Tremor, Feeling jittery, Pain in extremity, Wound, Cough, Muscular weakness, Pollakiuria, Nasopharyngitis, Gait disturbance, Hypoacusis, Nervousness, Screaming, Contusion, Emotional distress, Anger, Crying, Mental disorder, Anxiety, Headache, Rash, Feeling abnormal, Inappropriate schedule of product administration, |
||||
AMLODIPINE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, GABAPENTIN, OLANZAPINE, PRUCALOPRIDE SUCCINATE, PREDNISONE, ERGOCALCIFEROL, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, CALCIUM CARBONATE, ANTACID, PANTOPRAZOLE, |
||||
| 133 | 26910238 |
CA |
2 | |
Ovarian cancer, Malignant neoplasm progression, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), LETROZOLE, LETROZOLE TABLETS, APIXABAN, DULOXETINE HYDROCHLORIDE, DULOXETINE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, RISEDRONATE SODIUM, |
||||
| 134 | 26910393 |
JP |
72 | 1 |
Cholecystitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 135 | 26910419 |
JP |
81 | 1 |
Cholangitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 136 | 26910421 |
JP |
64 | 1 |
Cholangitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 137 | 26910521 |
CA |
59 | 2 |
Blood pressure increased, Syncope, Blood iron decreased, Cystitis, Cellulitis, Back pain, Neuralgia, Pain, Hypoaesthesia, Paraesthesia, Diabetes mellitus, Cholelithiasis, Haemorrhage, Hypothyroidism, Endometrial cancer stage I, Second primary malignancy, Nephrolithiasis, Renal impairment, Renal failure, Procedural pain, Carcinoid tumour, Metastases to ovary, Metastases to fallopian tube, Metastases to bladder, Malignant neoplasm progression, Palpitations, Arthralgia, Subcutaneous haematoma, Pain in extremity, Muscle spasms, Peripheral swelling, Serum serotonin increased, Vertigo, Urine output decreased, Myalgia, Contusion, Hepatic pain, Muscle tightness, Groin pain, Nasopharyngitis, White blood cell count increased, Haemoglobin decreased, Urinary tract infection, Acne, Liver function test increased, Hypomenorrhoea, Polyp, Blood urine present, Abdominal adhesions, Endometriosis, Endometrial hyperplasia, Poor quality sleep, Pyrexia, Chills, Cough, Migraine, Anaemia, Blood pressure systolic decreased, Blood pressure diastolic decreased, Joint swelling, Arthritis, Crystal arthropathy, Gout, Joint stiffness, Malaise, Peripheral swelling, Erythema, Joint swelling, Rash pruritic, Asthenia, Heart rate decreased, Vomiting, Dizziness, Abdominal pain, Abdominal tenderness, Rash papular, Diarrhoea, Fatigue, Nausea, Decreased appetite, Injection site mass, Injection site pain, Injection site pain, Injection site reaction, Injection site erythema, Needle issue, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, AMLODIPINE, AMLODIPINE, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CLOPIDOGREL, CLOPIDOGREL BISULFATE, |
||||
| 138 | 26910687 |
CA |
67 | 2 |
Metastases to lung, Malignant neoplasm progression, Ductal adenocarcinoma of pancreas, |
||||
IRINOTECAN HYDROCHLORIDE, OXALIPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 139 | 26910774 |
CO |
2 | |
Breast cancer metastatic, Malignant neoplasm progression, |
||||
LETROZOLE, RIBOCICLIB, |
||||
| 140 | 26910845 |
JP |
||
Pulmonary embolism, Malignant neoplasm progression, |
||||
DURVALUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 141 | 26910859 |
JP |
71 | 2 |
Cholangitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 142 | 26911007 |
BR |
66 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 143 | 26911016 |
JP |
71 | 2 |
Cholangitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 144 | 26911037 |
AR |
60 | 2 |
Metastasis, Malignant neoplasm progression, Metastases to bone, Metastases to lung, Metastases to liver, Chest discomfort, Pyrexia, Tumour marker increased, Adverse drug reaction, |
||||
FULVESTRANT, RIBOCICLIB, RIBOCICLIB, |
||||
| 145 | 26911364 |
BR |
70 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 146 | 26911771 |
JP |
6 | |
Myasthenia gravis, Malignant neoplasm progression, Hepatic function abnormal, |
||||
CABOZANTINIB, NIVOLUMAB, IPILIMUMAB, |
||||
| 147 | 26911919 |
CA |
59 | 2 |
Blood pressure increased, Syncope, Blood iron decreased, Cystitis, Cellulitis, Back pain, Neuralgia, Pain, Hypoaesthesia, Paraesthesia, Diabetes mellitus, Cholelithiasis, Haemorrhage, Hypothyroidism, Endometrial cancer stage I, Second primary malignancy, Nephrolithiasis, Renal impairment, Renal failure, Procedural pain, Carcinoid tumour, Metastases to ovary, Metastases to fallopian tube, Metastases to bladder, Malignant neoplasm progression, Palpitations, Arthralgia, Subcutaneous haematoma, Pain in extremity, Muscle spasms, Peripheral swelling, Serum serotonin increased, Vertigo, Urine output decreased, Myalgia, Contusion, Hepatic pain, Muscle tightness, Groin pain, Nasopharyngitis, White blood cell count increased, Haemoglobin decreased, Urinary tract infection, Acne, Liver function test increased, Hypomenorrhoea, Polyp, Blood urine present, Abdominal adhesions, Endometriosis, Endometrial hyperplasia, Poor quality sleep, Pyrexia, Chills, Cough, Migraine, Anaemia, Blood pressure systolic decreased, Blood pressure diastolic decreased, Joint swelling, Arthritis, Crystal arthropathy, Gout, Joint stiffness, Malaise, Peripheral swelling, Erythema, Joint swelling, Rash pruritic, Asthenia, Heart rate decreased, Vomiting, Dizziness, Abdominal pain, Abdominal tenderness, Rash papular, Diarrhoea, Fatigue, Nausea, Decreased appetite, Injection site mass, Injection site pain, Injection site pain, Injection site reaction, Injection site erythema, Needle issue, |
||||
AMLODIPINE, AMLODIPINE, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CLOPIDOGREL, CLOPIDOGREL BISULFATE, |
||||
| 148 | 26912208 |
BR |
58 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 149 | 26912230 |
US |
32 | 2 |
Anaplastic large cell lymphoma T- and null-cell types, Malignant neoplasm progression, Metastases to central nervous system, |
||||
PREDNISONE, BRENTUXIMAB VEDOTIN, CYTARABINE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, METHOTREXATE SODIUM, DEXAMETHASONE SODIUM PHOSPHATE, CISPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 150 | 26912290 |
US |
74 | 2 |
Colon cancer metastatic, Metastases to lung, Metastases to spine, Malignant neoplasm progression, |
||||
ENCORAFENIB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, TELMISARTAN, |
||||
| 151 | 26912813 |
JP |
72 | 1 |
Cholangitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 152 | 26912820 |
JP |
64 | 1 |
Cholangitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 153 | 26912946 |
JP |
82 | 2 |
Plasma cell myeloma, Malignant neoplasm progression, Cytomegalovirus infection, Fungal infection, Pneumonia, Varicella zoster pneumonia, Pneumonia bacterial, Radiation pneumonitis, Pneumonitis, Suspected off label use, |
||||
ELRANATAMAB-BCMM, ELRANATAMAB-BCMM, |
||||
| 154 | 26912962 |
JP |
||
Malignant neoplasm progression, |
||||
CAPIVASERTIB, FULVESTRANT, FULVESTRANT, |
||||
| 155 | 26912972 |
BR |
72 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 156 | 26913213 |
TW |
58 | 1 |
Hepatotoxicity, Malignant neoplasm progression, |
||||
PEMETREXED, PEMETREXED DISODIUM, CRIZOTINIB, |
||||
| 157 | 26913403 |
BR |
76 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 158 | 26913625 |
JP |
63 | 2 |
Cholangitis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 159 | 26913643 |
EU |
63 | 2 |
Diabetes mellitus, Gallbladder rupture, Malignant neoplasm progression, |
||||
LANREOTIDE ACETATE, |
||||
| 160 | 26913670 |
JP |
2 | |
Pneumonia, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 161 | 26913782 |
2 | ||
Malignant neoplasm progression, Brain radiation necrosis, Therapy partial responder, |
||||
| 162 | 26913783 |
US |
53 | 2 |
Malignant neoplasm progression, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 163 | 26913788 |
TW |
1 | |
Prostate cancer, Malignant neoplasm progression, Bone marrow disorder, Internal haemorrhage, Decreased immune responsiveness, Pneumonia, |
||||
| 164 | 26913932 |
BR |
82 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 165 | 26913936 |
70 | 2 | |
Malignant neoplasm progression, Jaundice cholestatic, Myelosuppression, |
||||
GEMCITABINE HYDROCHLORIDE, CISPLATIN, |
||||
| 166 | 26914464 |
TW |
67 | 2 |
Malignant neoplasm progression, Metastases to liver, Brain cancer metastatic, Adenocarcinoma, Neuropathy peripheral, Pleural mass, Dizziness, Headache, Myositis, |
||||
OSIMERTINIB, VINORELBINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, BRIGATINIB, |
||||
| 167 | 26904543 |
BR |
56 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 168 | 26905275 |
CA |
67 | 1 |
Malignant neoplasm progression, Transitional cell carcinoma metastatic, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 169 | 26905509 |
BR |
60 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 170 | 26905879 |
MX |
63 | 1 |
Malignant neoplasm progression, Transitional cell carcinoma metastatic, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 171 | 26906139 |
JP |
7 | 1 |
Malignant neoplasm progression, Oesophageal obstruction, Diarrhoea, Stomatitis, Oesophageal squamous cell carcinoma recurrent, |
||||
PEMBROLIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CISPLATIN, |
||||
| 172 | 26906424 |
RU |
78 | 1 |
Metastases to lymph nodes, Inappropriate schedule of product administration, Intervertebral disc disorder, Malignant neoplasm progression, |
||||
TRIPTORELIN, TRIPTORELIN, TRIPTORELIN, TRIPTORELIN, ENZALUTAMIDE, |
||||
| 173 | 26906809 |
TH |
72 | 2 |
Tumour marker increased, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
| 174 | 26906914 |
KR |
2 | |
Malignant neoplasm progression, Musculoskeletal chest pain, |
||||
OSIMERTINIB, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 175 | 26906965 |
MX |
73 | 2 |
Renal cancer, Malignant neoplasm progression, Off label use, |
||||
PAZOPANIB HYDROCHLORIDE, |
||||
| 176 | 26907205 |
CN |
61 | 1 |
Malignant neoplasm progression, Septic shock, Neutropenia, Confusional state, Leukopenia, Small intestinal obstruction, Gastrointestinal bacterial infection, Tremor, Immune-mediated lung disease, Pleural effusion, Cerebellar ataxia, Oesophageal haemorrhage, Hypoalbuminaemia, Myelosuppression, Paraneoplastic neurological syndrome, Gastrooesophageal reflux disease, Pneumonia, |
||||
NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, CISPLATIN, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 177 | 26907222 |
US |
1 | |
Malignant melanoma, Malignant neoplasm progression, |
||||
BINIMETINIB, |
||||
| 178 | 26907304 |
EU |
1 | |
Nervous system disorder, Chronic inflammatory demyelinating polyradiculoneuropathy, Cutaneous T-cell lymphoma, Malignant neoplasm progression, |
||||
BRENTUXIMAB VEDOTIN, |
||||
| 179 | 26908360 |
TW |
53 | 2 |
Malignant neoplasm progression, Abdominal hernia, Cholecystectomy, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 180 | 26908370 |
BR |
55 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 181 | 26908395 |
AU |
2 | |
Malignant neoplasm progression, Drug ineffective, Product use in unapproved indication, |
||||
DOSTARLIMAB, |
||||
| 182 | 26908777 |
EU |
1 | |
Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 183 | 26908783 |
JP |
80 | 1 |
Cholangitis, Malignant neoplasm progression, |
||||
DURVALUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, GLIMEPIRIDE, PIOGLITAZONE, LINAGLIPTIN, PITAVASTATIN CALCIUM, PITAVASTATIN, LANSOPRAZOLE, TAMSULOSIN HYDROCHLORIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 184 | 26908898 |
EU |
45 | 2 |
Malignant neoplasm progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 185 | 26909100 |
JP |
6 | 1 |
Pulmonary embolism, Malignant neoplasm progression, |
||||
IPILIMUMAB, NIVOLUMAB, |
||||
| 186 | 26909191 |
US |
67 | 1 |
Malignant neoplasm progression, Anaemia, Neutropenia, Thrombocytopenia, Febrile neutropenia, Infection, Sepsis, Product use issue, |
||||
IVOSIDENIB, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, |
||||
| 187 | 26909193 |
US |
61 | 2 |
Malignant neoplasm progression, Anaemia, Neutropenia, Febrile neutropenia, Thrombocytopenia, Sepsis, Product use issue, |
||||
IVOSIDENIB, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, |
||||
| 188 | 26909204 |
US |
61 | 2 |
Malignant neoplasm progression, Anaemia, Neutropenia, Thrombocytopenia, Febrile neutropenia, Infection, Product use issue, |
||||
IVOSIDENIB, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, |
||||
| 189 | 26909206 |
US |
67 | 2 |
Malignant neoplasm progression, Anaemia, Neutropenia, Thrombocytopenia, Febrile neutropenia, Sepsis, Product use issue, |
||||
IVOSIDENIB, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, |
||||
| 190 | 26909346 |
JP |
50 | 2 |
Death, Cholangitis sclerosing, Therapy partial responder, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, |
||||
| 191 | 26904327 |
JP |
64 | 1 |
Myelosuppression, Prostate cancer, Malignant neoplasm progression, Therapeutic product effect incomplete, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 192 | 26903280 |
EU |
61 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Hyperglycaemia, Drug ineffective, |
||||
FULVESTRANT, FULVESTRANT, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ALPELISIB, EMPAGLIFLOZIN, EMPAGLIFLOZIN, |
||||
| 193 | 26897558 |
BR |
64 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 194 | 26897614 |
IN |
2 | |
Decreased appetite, Malignant neoplasm progression, Sleep disorder, Pain, |
||||
DURVALUMAB, |
||||
| 195 | 26897901 |
BR |
82 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 196 | 26898049 |
EU |
2 | |
Immune-mediated enterocolitis, Immune-mediated hypophysitis, Pneumonia, Tumour pseudoprogression, Central hypothyroidism, Malnutrition, Malignant neoplasm progression, Pulmonary hilum mass, Atelectasis, Pleural effusion, Paratracheal lymphadenopathy, Pulmonary mass, |
||||
NIVOLUMAB, NIVOLUMAB, IPILIMUMAB, |
||||
| 197 | 26898300 |
EU |
62 | 2 |
Hypercalcaemia, Pulmonary artery thrombosis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, TRIFLURIDINE AND TIPIRACIL, |
||||
| 198 | 26898780 |
CN |
56 | 1 |
Renal cell carcinoma, Malignant neoplasm progression, Psychotic disorder, Drug intolerance, |
||||
PAZOPANIB HYDROCHLORIDE, |
||||
| 199 | 26898824 |
JP |
69 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 200 | 26898830 |
JP |
8 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, TRASTUZUMAB, CAPECITABINE, OXALIPLATIN, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30